Press Releases MEI Pharma, Inc.

Equities

MEIP

US55279B3015

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
3.05 ^USD	-1.61%		-6.15%	-47.41%

Apr. 11	MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data	CI
Apr. 11	MEI Pharma, Inc. Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab in Relapsed Metastatic Colorectal Cancer Patients	Apr. 12	AQ
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients	Apr. 11	BU
MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344	Apr. 11	BU
MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum	Apr. 10	BU
MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia	Mar. 26	BU
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)	Feb. 15	BU
MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights	Feb. 13	BU
MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024	Jan. 16	BU
MEI Pharma : Change in Certifying Accountants - Form 8-K	Dec. 26	PU
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)	Dec. 14	BU
MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023	Dec. 11	BU
MEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational Highlights	Nov. 09	BU
MEI Pharma to Present at the Stifel 2023 Healthcare Conference	Nov. 08	BU
MEI Pharma Declares Special Cash Dividend of $1.75 Per Share of Common Stock	Nov. 06	BU
MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023	Nov. 02	BU
MEI Pharma Enters into Agreement with Anson Funds and Cable Car Capital	Nov. 01	BU
MEI Pharma Recommends Stockholders Not to Consent	23-10-17	BU
MEI Pharma Adopts Limited-Duration Stockholder Rights Plan	23-10-02	BU
MEI Pharma Issues Statement Regarding Anson and Cable Car’s Opportunistic Actions	23-09-28	BU
MEI Pharma Reports Fiscal Year 2023 Results and Operational Highlights	23-09-26	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases MEI Pharma, Inc.

Equities

MEIP

US55279B3015

Press Releases

Filters